Drugs.com - Clinical Trials

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

BOSTON--(BUSINESS WIRE) April 14, 2025 -- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced...

Apr 14, 2025 - 22:06
 0
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
BOSTON--(BUSINESS WIRE) April 14, 2025 -- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced...
Read More

Tags:

Previous Article

No Mitsu for You: Brand Holds American Imports – for now

Next Article

Electrathon America Comes To Homestead-Miami Raceway

Related Posts

Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases with No Approved Medicines

Rilzabrutinib Granted Orphan Drug Designation in the US...

Apr 8, 2025  0

Arbor Biotechnologies Announces FDA Orphan Drug and Rare Pediatric Disease Designations Granted to ABO-101 for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

Arbor Biotechnologies Announces FDA Orphan Drug and Rar...

Feb 9, 2025  0

Boehringer’s Zongertinib Receives Priority Review from U.S. FDA for the Treatment of HER2 (ERBB2)-Mutant Advanced Non-Small Cell Lung Cancer

Boehringer’s Zongertinib Receives Priority Review from ...

Feb 20, 2025  0